NeuroSync, Inc.

NeuroSync develops objective, AI-powered digital health solutions for brain health assessment and performance optimization. The company's flagship product, EYE-SYNC, is an FDA-cleared platform that delivers rapid, portable eye-tracking and oculomotor testing for concussion diagnosis, neuro health evaluation, and performance monitoring. The platform comprises XR (extended reality) hardware, proprietary software with AI analytics, and customizable clinical reporting. Assessments complete in under one minute with 0.9 test-retest reliability, leveraging validated proprietary algorithms and quantification methods. NeuroSync serves healthcare systems, clinical research organizations, sports medicine programs, military/active duty personnel, and biopharma CNS trials. The platform is deployed at leading academic medical centers (Massachusetts General Hospital, Texas Health, Houston Methodist), collegiate athletic programs (Rice University, Georgia Tech, Virginia Tech), specialty neurology clinics, vestibular therapy centers, and professional sports organizations. Solutions address the gap in objective diagnostics for neurological conditions affecting over 83 million Americans annually. The wireless, portable design enables deployment in clinical, research, athletic, and field settings. NeuroSync markets to clinicians, researchers, high-performance specialists, and military medical personnel seeking objective, rapid brain health metrics for diagnosis, monitoring, and therapeutic planning.